Key Highlights
- $55 million raised in Series C financing to advance AB248, a novel cancer immunotherapy.
- New investors include AstraZeneca and Bristol Myers Squibb.
- Funds to support Phase 1 trials of AB248, targeting CD8+ T cells for various
Source: Business Wire
Notable Quotes
- “We are delighted to have the continued support of RA Capital, and excited to add two top biopharmaceutical companies and experts in oncology to our investor syndicate,” – Craig Gibbs, Ph.D., CEO at Asher Bio
- “Asher’s groundbreaking cis-targeting platform offers a highly differentiated approach to immunotherapy, with the potential to overcome the limitations of other immune-based treatments by maximizing efficacy and limiting off-target toxicities,” – Jake Simson at RA Capital Management
SoHC's Take
The successful closing of Asher Biotherapeutics’ Series C financing not only underscores the growing investor confidence in novel immunotherapies but also highlights the strategic importance of targeting precise immune responses in oncology. The inclusion of major pharmaceutical players as new investors reinforces the potential of Asher Bio’s technology platform to set new standards in the efficacy and safety of cancer treatment. The ongoing development and clinical trials of AB248 could be pivotal in transforming cancer treatment paradigms, particularly in enhancing the specificity and reducing the side effects of immunotherapies.
